Staining of MUC1 in ovarian cancer tissues with PankoMab-GEX™ detecting the tumour-associated epitope, TA-MUC1, as compared to antibodies HMFG-1 and 115D8
Staining of MUC1 in ovarian cancer tissues with PankoMab-GEX™ detecting the tumour-associated epitope, TA-MUC1, as compared to antibodies HMFG-1 and 115D8
复制标题
DOI：
10.14670/hh-28.239
复制
发表时间：
2013-02-01
影响因子：
2
通讯作者：
Jeschke, Udo
中科院分区：
文献类型：
--
作者：
Dian, Darius;Lenhard, Miriam;Jeschke, Udo
PankoMab-GEX （TM）是一种新的人源化糖优化抗体，可识别新的特异性肿瘤MUC1表位（TA-MUC1）。本研究的目的是评估PankoMab-GEX （TM）与多种卵巢癌标本（n=156）和正常卵巢组织的结合情况。此外，将PankoMab-GEX （TM）染色与众所周知的抗muc1抗体HMFG-1和115D8进行比较。PankoMab-GEX （TM）在浆液性癌（100%的病例，平均IRS 8.23）、子宫内膜样癌（95%的病例，平均IRS 6.40）、黏液性癌（58%的病例，平均IRS 4.17）和透明细胞癌（92%的病例，平均IRS 7.58）中显示阳性反应。与HMFG-1相比，PankoMab-GEX （TM）不能识别健康卵巢组织。115D8抗体染色随分期增加而增加。细胞质PankoMab-GEX （TM）染色随肿瘤分级而升高，但与分期无相关性。单因素Kaplan-Meier分析显示TA-MUC1高表达的患者有降低生存的趋势。这一发现令人鼓舞，因为PankoMab-GEX （TM）有可能成为卵巢癌患者的一种新的治疗性抗体。
PankoMab-GEX (TM) is a novel humanized and glycooptimized antibody, which recognizes a novel specific tumour epitope of MUC1 (TA-MUC1). The aim of this study was to evaluate PankoMab-GEX (TM) binding to a variety of ovarian cancer specimens (n=156) and to normal ovarian tissue. In addition, PankoMab-GEX (TM) staining was compared to that of the well-known anti-MUC1 antibodies HMFG-1 and 115D8. PankoMab-GEX (TM) showed positive reactivity in serous (100% of cases, mean IRS 8.23), endometrioid (95% of cases, mean IRS 6.40), mucinous (58% of cases, mean IRS 4.17), and clear cell (92% of cases, mean IRS 7.58) carcinomas. In contrast to HMFG-1, healthy ovarian tissue was not recognized by PankoMab-GEX (TM). Staining with antibody 115D8 was increased with staging. Cytoplasmic PankoMab-GEX (TM) staining increased with tumour grade, but no correlation was found with staging. Univariate Kaplan-Meier analysis revealed a tendency of reduced survival of patients with high expression of TA-MUC1. The findings are encouraging with respect to a potential use of PankoMab-GEX (TM) as a new therapeutic antibody for the treatment of ovarian cancer patients.